As a biomarker, PD-L1 expression levels on tumor tissue as measured by immunohistochemistry has been demonstrated as both a prognostic biomarker as well as predictive of response to anti-PD-1 therapy [9]. This evidence concerns the gene CD274 and neoplasm.